SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 5, 2025
JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2025.
Read more at globenewswire.com
